Deep remissions were frequent, with uMRD4 achieved in 86% (blood) and 84% (marrow), rising to 96% in both compartments among CR/CRi responders. Liso-cel CAR T plus ibrutinib delivers deep remissions ...

Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years. Sagar Lonial, MD, of the Winship Cancer Institute ...

HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...

The FDA granted accelerated approval to RP1 (vusolimogene oderparepvec; Tudriqev), an oncolytic virus therapy, in combination ...

ASCO 2026 data show ePRO remote symptom monitoring cuts ER visits and costs, enabling faster toxicity detection and safer ...

The FDA has cleared an investigational new drug (IND) application for Bria-PROS+, a personalized, off-the-shelf, whole-cell ...

Phase 3 SENOMAC randomized 2766 patients across five countries to completion ALND vs omission after up to two sentinel-node ...

Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how ...

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non ...

Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD discuss ...

Real-world ASCO 2026 data show ePRO-based remote monitoring helps catch metastatic cancer treatment symptoms earlier, ...

OncoPRO unites oncology practices to streamline ePRO remote symptom monitoring, improving enrollment, workflow integration, ...